Edwards Lifesciences (EW) Net Cash Flow (2009 - 2026)

Edwards Lifesciences has reported Net Cash Flow for 18 years, with the latest figure at -$500.2 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 564.44% year-over-year to -$500.2 million; the trailing twelve-month figure through Mar 2026 stood at -$682.4 million (down 135.75% YoY), and the FY2025 full-year result was -$74.5 million, down 103.98% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$500.2 million, down from $241.2 million in the prior quarter.
• The five-year high for Net Cash Flow was $2.1 billion in Q3 2024, with the low at -$675.6 million in Q4 2024.
• Average Net Cash Flow over 5 years is $90.7 million, with a median of $108.0 million recorded in 2023.
• Year-over-year, Net Cash Flow surged 827.79% in 2023 and sank 564.44% in 2026.
• Tracing EW's Net Cash Flow over 5 years: stood at -$460.9 million in 2022, then surged by 43.05% to -$262.5 million in 2023, then slumped by 157.37% to -$675.6 million in 2024, then soared by 135.7% to $241.2 million in 2025, then tumbled by 307.38% to -$500.2 million in 2026.
• The last three Net Cash Flow figures came in at -$500.2 million (Q1 2026), $241.2 million (Q4 2025), and -$594.2 million (Q3 2025), per Business Quant data.

Peer Comparison